Monoclonal antibodies targeting inflammatory pathways in COPD - evidence and opportunities - PubMed
4 hours ago
- #Inflammation
- #COPD
- #Monoclonal Antibodies
- COPD is a heterogeneous inflammatory lung disease with exacerbations driving global morbidity and mortality.
- While inhaled therapies are standard, many patients still experience exacerbations, highlighting the need for targeted monoclonal antibody therapies.
- Clinical trials targeting neutrophilic inflammation pathways (e.g., TNF, IL-1β, IL-17) have largely failed, but type-2 inflammation shows promise in a patient subset.
- Biomarkers like blood eosinophils and FeNO can identify patients likely to benefit from monoclonal antibodies such as dupilumab and mepolizumab.
- Emerging strategies focus on upstream mediators like alarmins (IL-33, TSLP) and bispecific therapies, with greatest benefit seen in moderate COPD patients with elevated eosinophils and FeNO.